Lucy Godson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lucy Godson has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Darren Treanor
Leeds Teaching Hospitals NHS Trust, Leeds, UK
3 shared publications - Andrew Broad
National Pathology Imaging Cooperative
2 shared publications Emily L. Clarke
University of Leeds
2 shared publicationsGraham P. Cook
University of Leeds
2 shared publications- Alexander Ian Wright
Leeds Institute of Cancer Studies and Pathology, University of Leeds, Leeds, United Kingdom
1 shared publication - Ali Gooya
School of Computing Science, University of Glasgow, Glasgow, U.K.
1 shared publication
Latest Publications
- 2 July 2026
- Published by Springer Nature
- p. 87-90
MIDOG 2025: Mitotic Figure Detection with Attention-Guided False Positive Correction
- 2 July 2026
- Published by Springer Nature
- p. 87-90
MIDOG 2025: Mitotic Figure Detection with Attention-Guided False Positive Correction
- Open Access
- 11 May 2026
- Published by SAGE Publications in Cancer Informatics
- Vol. 25
AI in Cancer Prognosis: A Systematic Review of Multimodal Models Combining Pathology Images and High-Throughput Omics
This study systematically reviews and evaluates published research on machine learning models that integrate histopathology whole slide images and high-throughput -omic data to predict overall survival in cancer. A comprehensive search of PubMed, EMBASE, and Cochrane CENTRAL was conducted through August 12, 2024, with citation screening for additional studies. Eligible studies applied machine learning or deep learning methods to multimodal data combining pathology images and -omics. Data extraction followed the CHARMS checklist, and risk of bias was assessed using the PROBAST + AI tool. Narrative synthesis was conducted in line with PRISMA 2020 guidelines. Forty-eight studies published since 2017 met inclusion criteria, spanning 19 cancer types. All relied on The Cancer Genome Atlas dataset. Modelling approaches included regularised Cox regression (n = 4), classical machine learning (n = 13), and deep learning (n = 31). Reported concordance indices ranged from 0.550 to 0.857, with most multimodal models outperforming unimodal counterparts. However, all studies were assessed as having high or unclear risk of bias—most often due to limited external validation, insufficient reporting, and minimal assessment of clinical utility. This review highlights a rapidly evolving yet methodologically underdeveloped field. While model performance is promising, improvements in data standardisation, reporting practices, and real-world contextualisation are critical for clinical translation. This work was funded by the National Pathology Imaging Cooperative (NPIC), supported by UK Research and Innovation (Project no. 104687).
- 11 May 2026
- Published by SAGE Publications in Cancer Informatics
- Vol. 25
Open AccessAI in Cancer Prognosis: A Systematic Review of Multimodal Models Combining Pathology Images and High-Throughput Omics
This study systematically reviews and evaluates published research on machine learning models that integrate histopathology whole slide images and high-throughput -omic data to predict overall survival in cancer. A comprehensive search of PubMed, EMBASE, and Cochrane CENTRAL was conducted through August 12, 2024, with citation screening for additional studies. Eligible studies applied machine learning or deep learning methods to multimodal data combining pathology images and -omics. Data extraction followed the CHARMS checklist, and risk of bias was assessed using the PROBAST + AI tool. Narrative synthesis was conducted in line with PRISMA 2020 guidelines. Forty-eight studies published since 2017 met inclusion criteria, spanning 19 cancer types. All relied on The Cancer Genome Atlas dataset. Modelling approaches included regularised Cox regression (n = 4), classical machine learning (n = 13), and deep learning (n = 31). Reported concordance indices ranged from 0.550 to 0.857, with most multimodal models outperforming unimodal counterparts. However, all studies were assessed as having high or unclear risk of bias—most often due to limited external validation, insufficient reporting, and minimal assessment of clinical utility. This review highlights a rapidly evolving yet methodologically underdeveloped field. While model performance is promising, improvements in data standardisation, reporting practices, and real-world contextualisation are critical for clinical translation. This work was funded by the National Pathology Imaging Cooperative (NPIC), supported by UK Research and Innovation (Project no. 104687).
- Open Access
Artificial Intelligence Devices for Image Analysis in Digital Pathology
B ackground: There is increasing momentum behind the clinical implementation of AI-based software for image analysis in digital pathology. As regulations, standards, and national approaches to the clinical use of AI continue to develop, the marketplace of AI products is expanding and evolving – presenting pathologists with a multitude of devices that offer the potential to improve pathology services. M ethods: To maintain pace with this changing AI device landscape, we conducted a comprehensive search for, and analysis of, commercial AI products for image analysis in digital pathology. This included CE-marked and Research Use Only (RUO) products using images with histological stains (e.g., H&E) or immunohistochemical (IHC) labelling. Product information and published clinical validation studies were assessed, to understand the quality of supporting evidence on available products, and product details were compiled into a public register: https://osf.io/gb84r/overview . R esults: In total, we identified and assessed 90 CE-marked and 227 RUO AI products. We found that AI products for cancer detection in prostate and breast pathology comprised a substantial portion of the marketplace for H&E image analysis, while IHC products were almost exclusively for use in breast cancer. Clinical validation studies on these products have steadily increased; however, we found that published studies were only available for just over half of H&E products and just over a quarter of IHC products. For CE-marked products, the dataset quality and diversity for AI model performance validation was highly variable, and particularly limited for IHC products. Furthermore, only a limited number of products included studies that assessed measures of clinical utility. C onclusion: As clinical deployment of AI products for image analysis in histopathology grows, there is a need for transparency, rigorous validation, and clear evidence supporting clinical utility and cost-effectiveness. Independent scrutiny of the expanding offering of AI products provides insight into the opportunities and shortcomings in this domain.
Open AccessArtificial Intelligence Devices for Image Analysis in Digital Pathology
B ackground: There is increasing momentum behind the clinical implementation of AI-based software for image analysis in digital pathology. As regulations, standards, and national approaches to the clinical use of AI continue to develop, the marketplace of AI products is expanding and evolving – presenting pathologists with a multitude of devices that offer the potential to improve pathology services. M ethods: To maintain pace with this changing AI device landscape, we conducted a comprehensive search for, and analysis of, commercial AI products for image analysis in digital pathology. This included CE-marked and Research Use Only (RUO) products using images with histological stains (e.g., H&E) or immunohistochemical (IHC) labelling. Product information and published clinical validation studies were assessed, to understand the quality of supporting evidence on available products, and product details were compiled into a public register: https://osf.io/gb84r/overview . R esults: In total, we identified and assessed 90 CE-marked and 227 RUO AI products. We found that AI products for cancer detection in prostate and breast pathology comprised a substantial portion of the marketplace for H&E image analysis, while IHC products were almost exclusively for use in breast cancer. Clinical validation studies on these products have steadily increased; however, we found that published studies were only available for just over half of H&E products and just over a quarter of IHC products. For CE-marked products, the dataset quality and diversity for AI model performance validation was highly variable, and particularly limited for IHC products. Furthermore, only a limited number of products included studies that assessed measures of clinical utility. C onclusion: As clinical deployment of AI products for image analysis in histopathology grows, there is a need for transparency, rigorous validation, and clear evidence supporting clinical utility and cost-effectiveness. Independent scrutiny of the expanding offering of AI products provides insight into the opportunities and shortcomings in this domain.
- 10 March 2024
- Published by Springer Nature
- p. 85-96
Multi-level Graph Representations of Melanoma Whole Slide Images for Identifying Immune Subgroups
- 10 March 2024
- Published by Springer Nature
- p. 85-96
Multi-level Graph Representations of Melanoma Whole Slide Images for Identifying Immune Subgroups
- Open Access
- 1 February 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 93, 103097
Immune subtyping of melanoma whole slide images using multiple instance learning
- 1 February 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 93, 103097
Open AccessImmune subtyping of melanoma whole slide images using multiple instance learning